Cantor Fitzgerald Reaffirms “Neutral” Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “neutral” rating restated by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday,Benzinga reports.

Other research analysts also recently issued reports about the stock. Rodman & Renshaw started coverage on shares of Omeros in a research report on Thursday. They issued a “buy” rating and a $9.00 price target on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Thursday. Finally, StockNews.com cut Omeros from a “hold” rating to a “sell” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $9.00.

Omeros Stock Down 2.9 %

NASDAQ OMER opened at $6.75 on Thursday. The company has a 50-day moving average price of $4.08 and a 200-day moving average price of $4.07. Omeros has a 52 week low of $1.38 and a 52 week high of $7.51. The firm has a market capitalization of $391.14 million, a P/E ratio of -2.92 and a beta of 1.47.

Institutional Investors Weigh In On Omeros

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Omeros by 2.6% during the first quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock worth $11,213,000 after purchasing an additional 81,348 shares in the last quarter. Wellington Management Group LLP bought a new position in Omeros in the 3rd quarter worth approximately $305,000. Barclays PLC grew its holdings in Omeros by 121.3% during the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after buying an additional 51,873 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Omeros by 16.6% during the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after buying an additional 31,081 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new position in shares of Omeros in the second quarter worth $105,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.